Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Breast Biopsy Devices: Interventional Medicine Comes to Breast Cancer

This article was originally published in Start Up

Executive Summary

In breast cancer, the need for less invasive alternatives to surgery is gaping, particularly on the diagnostic side. Following routine screening mammography, 1.4 million women in the US each year have breast biopsies once a radiologist identifies a suspicious lesion. However, only 20% of women undergoing biopsies will be found to have cancer and not just abnormal, but benign growths. Several new companies have gone to the drawing board to remedy the shortcomings of biopsy devices.

You may also be interested in...



Suros Surgical Systems Inc.

J&J Subsidiary Biopsys pioneered minimally-invasive breast core biopsy and was the lone player in the market for years. But now, Suros Surgical Systems has launched a competing vacuum-assisted biopsys system that is making incursions on J&J's market share with an improved technology that is the first that is suitable for MRI-guided breast biopsy.

Artemis Medical Inc.

Artemis Medical hopes to combine the diagnostic accuracy of surgical biopsy with the comfort and rapid healing time of minimally invasive biopsy, with a device that can remove an architecturally intact 12mmX 14mm sample of tissue through a 6mm skin opening.

BioLuminate Inc.

Every week just under 19,000 breast biopsies are performed in the US to find only 2,800 cancers. While tissue biopsies will always be necessary to determine the degree, invasiveness and stage of masses that are cancerous, the founder of BioLuminate thought there ought to be a less invasive way to initially rule out cancer to prevent large numbers of biopsies on benign tissue. He believes he's found it in smart probe technology licensed from NASA.

Topics

Related Companies

Related Deals

Latest News
See All
UsernamePublicRestriction

Register

MT037270

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel